Nkarta, Inc.
NKTX
Last
$2.25
Day
+1.4%
1y
-5.9%
5y
-91.4%
52w
-40.3%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-0929d
EMA 21
2.56
EMA 50
2.63
EMA 200
2.57
20d high
-27.9%
5y high
-91.7%
5y range
4th
Positions held
Your positionsNKTX isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-16
Hold
avoid
Signal
Strong Sell
Target
$2.51
Stop
$1.98
Stop distance
12.0%
Target vs last
+11.6%
Fundamentals
| Market cap | $159.01M | Enterprise value | $49.78M | Trailing P/E | — | Forward P/E | -1.27 |
| PEG | — | Price / book | 0.64 | Beta | 0.94 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -38.8% | ROA | -19.6% | Debt / equity | 0.30 |
| Current ratio | 7.98 | Free cash flow | -$55.13M | Analyst recommendation | strong_buy | Mean target | $10.83 |
| 52w high | $3.72 | 52w low | $1.70 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$40.4M | -$27.8M | -$27.4M | -$21.7M | -$23.0M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$43.1M | -$30.9M | -$31.0M | -$27.3M | -$27.2M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$104M | -$109M | -$118M | -$114M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$122M | -$128M | -$132M | -$119M |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-27 · Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance
2026-09-10 · Nkarta to Participate in September Investor Conferences
2026-08-10 · Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
2026-07-23 · Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
Price (daily)
Full chart · RSI · MACD · patternsNKTX · daily-24.7% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin